Innovation Acta SRL

Where the EU money came from

Funding by EU programme. Amounts are Innovation Acta SRL's own share of each project, not the project's full budget.

Projects

31 EU-funded projects, newest first. Each links to the official record.

• GlycoAxisAssociated partner

  Training the next generation of scientists on cell surface Glycans from Gram-negative gut microbiota as molecular keys to decOde the gut-immune-brain Axis

  Horizon Europe · 2027–2030 · Project on CORDIS ↗
• THANATOSPartner

  THERAPEUTIC ANTIBODIES NEUTRALIZING ALL THE ORTHOPOXVIRUS INFECTIOUS FOR HUMANS, INCLUDING SMALLPOX

  Horizon Europe · 2026–2031 · Project on CORDIS ↗

  €359ktheir share
• BIO2Partner

  NATURAL BIO-MASS AND MICROBIAL BIO-CONTROL AGENT SOLUTIONS FOR THE REPLACEMENT OF CONTENTIOUS INPUTS IN ORGANIC FARMING

  Horizon Europe · 2025–2029 · Project on CORDIS ↗

  €132ktheir share
• AUREUSAssociated partner

  wAll teichoic acids as immUnogenic and conseRved altErnative targets for therapies versUs S. aureus

  Horizon Europe · 2025–2029 · Project on CORDIS ↗
• INSIDE:INSIGHTAssociated partner

  The integration of technology with medical and healthcare education - a leadership program

  Horizon Europe · 2025–2028 · Project on CORDIS ↗
• InFlaMePartner

  Counter-acting the pandemic potential of flaviviruses: addressing virus-host interactions and defense strategies to design new therapeutics against WNV and DENV

  Horizon Europe · 2025–2028 · Project on CORDIS ↗

  €250ktheir share
• BactEradiXPartner

  Advanced nanomaterials to target genomic and Z-DNA for bacterial biofilm eradication

  Horizon Europe · 2024–2028 · Project on CORDIS ↗

  €303ktheir share
• SECRETAssociated partner

  Exploring the therapeutic potential of perinatal cell SECRETomes

  Horizon Europe · 2024–2028 · Project on CORDIS ↗
• LIVERAIMPartner

  A Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy

  Horizon Europe · 2024–2030 · Project on CORDIS ↗

  €500ktheir share
• GLYCO-NAssociated partner

  GLYCOprotein N-glycosylation from non-life to eukaryotes: a Doctoral Network to expand the knowledge on a ubiquitous posttranslational modification of proteins

  Horizon Europe · 2024–2028 · Project on CORDIS ↗
• GlyCanDrugAssociated partner

  A training network on the design of precision therapeutics that target key glycan motifs implicated in cancer

  Horizon Europe · 2023–2027 · Project on CORDIS ↗
• THRIVEPartner

  TUMOUR-HOST INTERACTIONS IN LIVER CANCER OF CHILDHOOD AND ADULTS

  Horizon Europe · 2023–2028 · Project on CORDIS ↗

  €365ktheir share
• TOP-GUTAssociated partner

  Training for Organoids modelling Physiology and Pathology in the human gastrointestinal tract

  Horizon Europe · 2023–2027 · Project on CORDIS ↗
• B-specificPartner

  B-specific: B-cell related gene and protein markers with prognostic and therapeutic value for CVD

  Horizon Europe · 2023–2027 · Project on CORDIS ↗

  €202ktheir share
• exTraAssociated partner

  Innovative Applications of Extracorporeal Photopheresis in Solid Organ Transplantation

  Horizon Europe · 2023–2027 · Project on CORDIS ↗
• IMMUTOLPartner

  ADVANCED ANTIGEN-SPECIFIC DENDRITIC CELL-BASED THERAPY TO RE-ESTABLISH TOLERANCE IN IMMUNE-MEDIATED DISEASES

  Horizon Europe · 2023–2027 · Project on CORDIS ↗

  €376ktheir share
• GUIDE.MRDPartner

  GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD

  Horizon Europe · 2023–2028 · Project on CORDIS ↗

  €378ktheir share
• CohesiNetAssociated partner

  Cohesin and its regulators: from chromosome dynamics and nuclear architecture to human diseases

  Horizon Europe · 2023–2027 · Project on CORDIS ↗
• PROTOPartner

  PROTO - Advanced PeRsOnalized Therapies for Osteoarthritis – TACKLING INFLAMMATION TO IMPROVE PATIENT OUTCOMES

  Horizon Europe · 2023–2027 · Project on CORDIS ↗

  €303ktheir share
• TOLERATEAssociated partner

  An integrated approach to restore tolerance in autoimmune disease

  Horizon Europe · 2022–2026 · Project on CORDIS ↗
• T-FITNESSPartner

  FINE-TUNING T CELL NETWORKS OF EXHAUSTION BY SYNTHETIC SENSORS

  Horizon Europe · 2022–2027 · Project on CORDIS ↗

  €235ktheir share
• geneTIGAPartner

  Gene-edited T cells combating IgA Nephropathy. A blueprint approach for safe & efficient genome editing of T cells to sustainably combat several immune diseases and cancers related to B-cell pathology

  Horizon Europe · 2022–2026 · Project on CORDIS ↗

  €599ktheir share
• HDM-FUNPartner

  Host directed medicine in invasive fungal infection

  Horizon 2020 · 2020–2026 · Project on CORDIS ↗

  €351ktheir share
• LiverScreenPartner

  Screening for liver fibrosis - population-based study across European countries

  Horizon 2020 · 2020–2025 · Project on CORDIS ↗

  €226ktheir share
• RESTOREPartner

  RESTORE Health by Advanced Therapies (Advanced Therapy Medicinal Products and Biologized Medical Devices) – ALL for Advanced Therapies – with Passion – For Patients

  Horizon 2020 · 2019–2020 · Project on CORDIS ↗

  €588ktheir share
• NECESSITYPartner

  NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients

  Horizon 2020 · 2019–2025 · Project on CORDIS ↗

  €300ktheir share
• RESHAPEPartner

  Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

  Horizon 2020 · 2019–2024 · Project on CORDIS ↗

  €426ktheir share
• INTEGRATAPartner

  Integrating chemical and biological approaches to target NAD production and signaling in cancer

  Horizon 2020 · 2018–2023 · Project on CORDIS ↗
• HIPGENPartner

  Placenta-expanded adherent stromal cells (PLX-PAD) as an innovative therapy for improving recovery and survival following hip fracture arthroplasty – HIPGEN, a multicenter phase III trial

  Horizon 2020 · 2018–2022 · Project on CORDIS ↗

  €83ktheir share
• LIVERHOPEPartner

  SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS

  Horizon 2020 · 2017–2023 · Project on CORDIS ↗

  €37ktheir share
• PACEPartner

  A multicenter phase IIb study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischemia accompanied by mechanistic studies

  Horizon 2020 · 2017–2021 · Project on CORDIS ↗

  €68ktheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

• Charite - Universitaetsmedizin BerlinGermany · 7 shared projects
• Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i SunyerSpain · 7 shared projects
• Stichting Amsterdam UmcNetherlands · 5 shared projects
• Assistance Publique Hopitaux de ParisFrance · 5 shared projects
• Katholieke Universiteit LeuvenBelgium · 4 shared projects
• Universitat ZurichSwitzerland · 4 shared projects
• University of Newcastle Upon TyneUnited Kingdom · 4 shared projects
• Universidade do MinhoPortugal · 4 shared projects
• Pluri Biotech LtdIsrael · 4 shared projects
• Tissuse GmbHGermany · 4 shared projects
• Hospital Clinic de BarcelonaSpain · 4 shared projects
• European Liver Patients AssociationBelgium · 4 shared projects
• Centre National de la Recherche Scientifique CNRSFrance · 3 shared projects
• The Chancellor, Masters and Scholars of the University of OxfordUnited Kingdom · 3 shared projects
• Agencia Estatal Consejo Superior de Investigaciones CientificasSpain · 3 shared projects
• Consiglio Nazionale Delle RicercheItaly · 3 shared projects

Fields it works in

Research fields recorded on its Horizon projects.

• DNA
• HIV
• antibiotic resistance
• antibiotics
• antivirals
• arteriosclerosis
• artificial intelligence
• autoimmune diseases
• bacteriology
• carbohydrates
• cell biology
• cells technologies
• chromosomes
• diabetes